NORTHERN TRUST CORP - MERRIMACK PHARMACEUTICALS IN ownership

MERRIMACK PHARMACEUTICALS IN's ticker is MACK and the CUSIP is 590328209. A total of 51 filers reported holding MERRIMACK PHARMACEUTICALS IN in Q4 2022. The put-call ratio across all filers is 0.61 and the average weighting 0.5%.

Quarter-by-quarter ownership
NORTHERN TRUST CORP ownership history of MERRIMACK PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2023$1,422,499
-0.3%
115,369
-0.5%
0.00%
Q2 2023$1,426,702
+315.4%
115,992
+315.0%
0.00%
Q1 2023$343,481
+16.1%
27,948
+8.2%
0.00%
Q4 2022$295,920
+228.8%
25,822
+7.7%
0.00%
Q3 2022$90,000
-36.6%
23,980
+0.7%
0.00%
Q2 2022$142,000
-10.7%
23,803
-5.0%
0.00%
Q1 2022$159,000
+62.2%
25,063
-0.3%
0.00%
Q4 2021$98,000
-19.0%
25,1510.0%0.00%
Q3 2021$121,000
-40.4%
25,151
-20.6%
0.00%
Q2 2021$203,000
-11.0%
31,678
-12.5%
0.00%
Q1 2021$228,000
-7.7%
36,213
+0.9%
0.00%
Q4 2020$247,000
+69.2%
35,890
-2.0%
0.00%
Q3 2020$146,000
+5.0%
36,632
-12.3%
0.00%
Q2 2020$139,000
-18.7%
41,786
-47.6%
0.00%
Q1 2020$171,000
-31.9%
79,669
-0.2%
0.00%
Q4 2019$251,000
-30.3%
79,801
-0.2%
0.00%
Q3 2019$360,000
-26.7%
79,946
-1.5%
0.00%
Q2 2019$491,000
-12.8%
81,167
+0.1%
0.00%
Q1 2019$563,000
+141.6%
81,048
+34.1%
0.00%
Q4 2018$233,000
-12.7%
60,417
+20.5%
0.00%
Q3 2018$267,000
+9.9%
50,154
+1.3%
0.00%
Q2 2018$243,000
-81.1%
49,498
-69.0%
0.00%
Q1 2018$1,284,000
-16.2%
159,477
+6.7%
0.00%
Q4 2017$1,533,000
-28.8%
149,521
+0.9%
0.00%
-100.0%
Q3 2017$2,154,000148,1510.00%
Other shareholders
MERRIMACK PHARMACEUTICALS IN shareholders Q4 2022
NameSharesValueWeighting ↓
Western Standard LLC 869,354$2,895,0003.47%
22NW, LP 1,241,896$4,136,0002.24%
Newtyn Management, LLC 1,199,606$3,995,0001.46%
WITTENBERG INVESTMENT MANAGEMENT, INC. 186,198$620,0000.35%
Yakira Capital Management, Inc. 66,934$223,0000.10%
Sepio Capital, LP 210,534$701,0000.08%
Nantahala Capital Management 747,635$2,490,0000.08%
Watson Rebecca 3,068$10,0000.01%
BRIDGEWAY CAPITAL MANAGEMENT, LLC 61,700$205,0000.00%
WEBSTER BANK, N. A. 3,055$10,0000.00%
View complete list of MERRIMACK PHARMACEUTICALS IN shareholders